Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection.
Saved in:
| Title: | Cabotegravir: a novel HIV integrase inhibitor combined with rilpivirine as the first long-acting injectable program for the treatment of HIV infection. |
|---|---|
| Authors: | Zeuli JD; HIV Program, Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.; Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA. zeuli.john@mayo.edu., Rivera CG; HIV Program, Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.; Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA., Smith BL; Department of Pharmacy, Grady Health System, Atlanta, Georgia, USA., Otto A; Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA., Temesgen Z; HIV Program, Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA. |
| Source: | Drugs of today (Barcelona, Spain : 1998) [Drugs Today (Barc)] 2022 Dec; Vol. 58 (12), pp. 555-576. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Clarivate Analytics Country of Publication: Spain NLM ID: 101160518 Publication Model: Print Cited Medium: Print ISSN: 1699-3993 (Print) Linking ISSN: 16993993 NLM ISO Abbreviation: Drugs Today (Barc) Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
